GSK plc
$162.15B- Market cap
- $106.03B
- Debt
- +$44.87B
- Cash
- −$3.40B
Capital structure 70% equity / 30% debt · EV / Revenue 3.67x · EV / EBITDA 19.05x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $106.03B · View financials
Snapshot Sep 8, 10:05 AM ET
FY 2025 ·
Decision snapshot: GSK stock price at discount vs SUPN $49.14 current versus $75.87 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at SUPN's multiple
Implied fair value · at GSK's multiple
Snapshot Sep 8, 10:02 AM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: GSK FY 2025 (ended Dec 31, 2025) · SUPN FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 70% equity / 30% debt · EV / Revenue 3.67x · EV / EBITDA 19.05x
Capital structure 98% equity / 2% debt · EV / Revenue 3.36x · EV / EBITDA 49.89x
GSK carries the larger enterprise value at $162.15B against $2.41B; SUPN trades on the lower EV / Revenue multiple (3.36x vs 3.67x); GSK on the lower EV / EBITDA (19.05x vs 49.89x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
GSK plc · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
SUPERNUS PHARMACEUTICALS, INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
—
0.04x
Net debt / EBITDA
Leverage against operating earnings
6.59x
-1.75x
Cash and equivalents
Liquid reserves on the balance sheet
$3.40B
$128.45M
Total debt
Interest-bearing obligations outstanding
$44.87B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PFIZER INC
GSK vs PFE
ELI LILLY & Co
GSK vs LLY
BRISTOL MYERS SQUIBB CO
GSK vs BMY
JOHNSON & JOHNSON
GSK vs JNJ
AbbVie Inc.
GSK vs ABBV
AMGEN INC
GSK vs AMGN
Jazz Pharmaceuticals plc
GSK vs JAZZ
INCYTE CORP
GSK vs INCY
ANI PHARMACEUTICALS INC
GSK vs ANIP
Vanda Pharmaceuticals Inc.
GSK vs VNDA
Harmony Biosciences Holdings, Inc.
GSK vs HRMY
$43.80M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.